Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | PRMT1 | Q99873 | 13/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 4/20 | 0.36 |
| ▸ | PRMT8 | Q9NR22 | 2/20 | 0.36 |
| ▸ | CARM1 | Q86X55 | 4/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
| ▸ | MOK | Q9UQ07 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19428298 | 0.89 | PRMT6 (0.43) | PDE3BPDE3APRMT1PRMT6PRMT8 | |
| SCHEMBL19432080 | 0.86 | PDE3B (0.39) | PDE3BPDE3APRMT1PRMT6PRMT8 | |
| SCHEMBL16128988 | 0.85 | XDH (0.44) | PDE3BPDE3APRMT1PRMT6PRMT8 | |
| SCHEMBL16128987 | 0.84 | S1PR1 (0.38) | PDE3BPDE3APRMT1PRMT6PRMT8 | |
| SCHEMBL16127557 | 0.83 | PRMT6 (0.33) | PRMT1PRMT6PRMT8 | |
| SCHEMBL16131412 | 0.82 | PRMT6 (0.42) | PDE3BPDE3APRMT1PRMT6PRMT8 | |
| SCHEMBL19432193 | 0.82 | PRMT1 (0.42) | PRMT1PRMT6PRMT8CARM1 | |
| SCHEMBL16129025 | 0.80 | PDE3B (0.41) | PDE3BPDE3APRMT1PRMT6PRMT8 | |
| SCHEMBL16204270 | 0.80 | PRMT6 (0.37) | PRMT1PRMT6PRMT8CARM1 | |
| SCHEMBL16129012 | 0.80 | S1PR1 (0.39) | PDE3BPDE3APRMT1PRMT6PRMT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190077795-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| EP-2970134-B1 | PYRAZOLE DERIVATIVES AS PRMT1 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20160039767-A1 | PYRAZOLE DERIVATIVES AS PRMT1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-02-11 | — | — | US | disclosed |
| US-8952026-B2 | PRMT1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20140288140-A1 | PRMT1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039767-A1 | PYRAZOLE DERIVATIVES AS PRMT1 INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | PDE3B 629/4885PDE3A 583/4885PRMT1 1/4885 |
| US-20190077795-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | PDE3B 420/4885PDE3A 293/4885PRMT1 1/4885 |
| US-20140288140-A1 | PRMT1 INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT6 | PDE3B 999/4885PDE3A 899/4885PRMT1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.